Meda acquires Pyralvex, Spasmonal and Waxsol from Norgine

Meda (STO:MEDAA) has acquired three well established OTC products from Norgine, a Dutch pharma company. The products are Pyralvex (relief of pain associated with e.g. aphthous ulcers), Spasmonal (treatment of for example Irritable Bowel Syndrome) and Waxsol (ear drops). The largest product is Pyralvex, which has a turnover of about 90 MSEK. Total annual sales for the products are about 190 MSEK and the majority of sales are generated in Europe. The purchase price is 540 MSEK which equals an EBITDA multiple of about 5.

"OTC products is a growing segment. This acquisition of well known OTC brands further strengthens our presence in this area", said Anders Lönner, CEO Meda.


MEDA AB (publ)


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment